Logo

Seagen Presents Results of Tukysa (tucatinib) + Trastuzumab in P-II (MOUNTAINEER) Trial for HER2-Positive Metastatic Colorectal Cancer at ESMO 2022

Share this
Seagen Presents Results of Tukysa (tucatinib) + Trastuzumab in P-II (MOUNTAINEER) Trial for HER2-Positive Metastatic Colorectal Cancer at ESMO 2022

Seagen Presents Results of Tukysa (tucatinib) + Trastuzumab in P-II (MOUNTAINEER) Trial for HER2-Positive Metastatic Colorectal Cancer at ESMO 2022

Shots:

  • The P-II (MOUNTAINEER) trial evaluates tucatinib + trastuzumab or as monothx. in 117 patients with HER2+ metastatic or unresectable colorectal cancer
  • The results showed that the combination therapy was found to be well-tolerated with durable responses. At a median duration of follow-up of 20.7mos., cORR (38.1%), m-DoR was 12.4mos., m-PFS was 8.2mos. & m-OS was 24.1mos., 64.3% & 70.2% had liver or lung metastases & had received a median of 3.0 prior lines of systemic therapy
  • In a cohort of patients who received tucatinib monothx., ORR (3.3%) @12wk. & DCR (80.0%), patients had the option to receive the combination therapy if they did not respond to tucatinib monothx., AEs leading to discontinuation (5.8%) with no deaths due to AEs

Ref: Bussinesswire | Image: Seagen

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions